Cell-free DNA Methylome Analysis Enables Early Preeclampsia Prediction
This dataset contains in solution target-enrichment bisulfite sequencing of placental tissue, buffy coat and plasma DNA from pregnant women. Blood samples were taken for cell-free DNA (cfDNA) DNA extraction from 64 women at the time of early-onset preeclampsia (PE) diagnosis, or from 38 controls (uncomplicated pregnancies) at a similar gestational age that did not develop preeclampsia subsequently. Among these subjects, plasma samples from 7 PE patients and 6 controls were also subjected to oxidative bisulfite sequencing. Placental tissues from 11 PE and 26 control subjects after delivery, and buffy coat from 16 PE and 16 control subjects at the same time of cfDNA sampling were profiled. A discovery cohort for early PE assessment in the first trimester was collected. In this cohort, cfDNA from 75 pregnancies that went on to develop early-onset PE and from 124 matched controls were collected and methylome sequencing were carried out. An independent validation cohort to validate early PE assessment with methylome profiling was collected as well. This validation cohort includes cfDNA samples from 61 PE and 136 control pregnancies.
- 604 samples
- DAC: EGAC00001003153
- Technology: Illumina NovaSeq 6000
UZ Leuven data access policy
The procedure described below always applies to re-use transfer of genomic or genetic data that are in an external database. This external database can be the European Genome-phenome Archive (EGA). When a researcher receives requests for reuse of data, or when the database requires an intervention of a data access committee, the DAC will assess these requests for reuse and transfer of genomic or genetic data by third parties. Patient consent to research participation (ICF) and compatibility with new data processing should be checked. An application should be submitted at dac@uzleuven.be. So applications for re-use of genomic/genomic data go through the DAC. In the first place, DAC performs a front desk function here. An application form should be completed by the applicant. To begin with, the DAC employee then checks the ICF and its compatibility with further use. The DAC employee also ensures that a check is made with the competent services to ensure that there are no legal impediments. If i) there are possible commercial interests (commercial use of the data by the recipient or the requesting party is a commercial party), ii) the researcher does not agree, or iii) there is some ambiguity about potential risks of the data transfer (e.g. violation (GDPR) legislation, identity of recipient party, use of the data), the question is referred to the DAC advisory board.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |